← Leaderboards
Douglas F Nixon
J. David Gladstone Institutes
$54,453,314
Attributed
$65,844,525
Total exposure
27
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.2M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$67,202,762 · 28
By mechanism
UM1$28,083,864 · 1
R01$23,925,797 · 10
P01$3,320,698 · 2
R21$3,303,601 · 7
R37$3,147,846 · 1
R56$3,141,350 · 3
Top collaborators
- Ethel Cesarman6 shared
- Lishomwa C Ndhlovu6 shared
- Susana T Valente5 shared
- Timothy Powell4 shared
- R. Brad Jones2 shared
- Michael Jay Corley1 shared
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- Robert M. Grant$57,229,912
- Ya-Lin Chiu$270,000
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsHiv InfectionsInfectionImmune ResponseIn VitroT-LymphocyteResponseVirusCd4 Positive T LymphocytesViralGrantHiv-1PhenotypePathogenesisViral Load ResultMediatingImmuneLeadEpitopesProgramsResearch PersonnelCell PhysiologyPersonsBase
Grant awards (110)
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,064,245
R01 · FY2025 · CA · contact PI
Single cell dark matter in the context of HIV and substance use$616,372
R01 · FY2025 · DA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$108,000
R01 · FY2025 · CA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,116,963
R01 · FY2024 · CA · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuseand Aging on Cognitive Impairment$738,817
R01 · FY2024 · DA · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$1
R01 · FY2024 · DA · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,178,126
R01 · FY2023 · CA · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$737,501
R01 · FY2023 · DA · contact PI
ConProject-001$1,358,238
R56 · FY2022 · AG · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,178,618
R01 · FY2022 · CA · contact PI
The Role of Transposable Elements in Healthy Aging and in Alzheimer's Disease$1,012,723
R56 · FY2022 · AG · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$736,183
R01 · FY2022 · DA · contact PI
The Role of Transposable Elements in Healthy Aging and in Alzheimer's Disease$345,514
R56 · FY2022 · AG · contact PI
Novel approaches for relating genetic variation in endogenous retroviruses to function and disease$211,875
R21 · FY2022 · HG · contact PI
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma$1,200,301
R01 · FY2021 · CA · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$734,866
R01 · FY2021 · DA · contact PI
Novel approaches for relating genetic variation in endogenous retroviruses to function and disease$254,250
R21 · FY2021 · HG · contact PI
Genetic Risk of HIV Acquisition: Mechanisms of Resilience$211,875
R21 · FY2021 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,680,664
UM1 · FY2020 · AI · contact PI
Development of Brain Organoids to Study the Impact of HIV-1, Drugs of Abuse and Aging on Cognitive Impairment$750,923
R01 · FY2020 · DA · contact PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers$366,779
R01 · FY2020 · CA · contact PI
Genetic Risk of HIV Acquisition: Mechanisms of Resilience$254,250
R21 · FY2020 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,555,460
UM1 · FY2019 · AI · contact PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers$371,373
R01 · FY2019 · CA · contact PI
SWG 2: Cure Research Scientific Working Group$21,475
P30 · FY2019 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,797,611
UM1 · FY2018 · AI · contact PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers$410,576
R01 · FY2018 · CA · contact PI
Core C: Basic Sciences Core$169,935
P30 · FY2018 · AI · contact PI
SWG 2: Cure Research Scientific Working Group$18,808
P30 · FY2018 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,334,612
UM1 · FY2017 · AI · contact PI
Elimination of HIV using HERV specific T cells$593,187
R01 · FY2017 · AI · contact PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers$508,654
R01 · FY2017 · CA · contact PI
Core C: Basic Sciences Core$149,393
P30 · FY2017 · AI · contact PI
SWG 2: Cure Research Scientific Working Group$18,698
P30 · FY2017 · AI · contact PI
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral Eradication$5,715,517
UM1 · FY2016 · AI · contact PI
HIV induced anti-cancer HERV immunity in prostate, breast and colon cancers$531,650
R01 · FY2016 · CA · contact PI
Elimination of HIV using HERV specific T cells$456,244
R01 · FY2016 · AI · contact PI
Innate NKT Cells in HIV Infection$326,844
R37 · FY2016 · AI · contact PI
Core C: Basic Sciences Core$175,019
P30 · FY2016 · AI · contact PI
SWG 2: Cure Research Scientific Working Group$14,504
P30 · FY2016 · AI · contact PI
A novel APOBEC-based vaccine approach for HIV$753,200
R33 · FY2015 · AI · contact PI
Elimination of HIV using HERV specific T cells$469,915
R01 · FY2015 · AI · contact PI
Innate NKT Cells in HIV Infection$327,200
R37 · FY2015 · AI · contact PI
Core C: Basic Sciences Core$172,738
P30 · FY2015 · AI · contact PI
SWG 2: Cure Research Scientific Working Group$15,135
P30 · FY2015 · AI · contact PI
A novel APOBEC-based vaccine approach for HIV$770,701
R33 · FY2014 · AI · contact PI
Elimination of HIV using HERV specific T cells$484,540
R01 · FY2014 · AI · contact PI
Innate NKT Cells in HIV Infection$332,822
R37 · FY2014 · AI · contact PI
Innate NKT Cells in HIV Infection$311,506
R37 · FY2013 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$221,244
R01 · FY2013 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$140,773
R01 · FY2013 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$381,538
R01 · FY2012 · AI · contact PI
Innate NKT Cells in HIV Infection$330,671
R37 · FY2012 · AI · contact PI
A novel APOBEC-based vaccine approach for HIV$217,056
R21 · FY2012 · AI · contact PI
A novel APOBEC-based vaccine approach for HIV$19,616
R21 · FY2012 · AI · contact PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection$421,403
P01 · FY2011 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$375,138
R01 · FY2011 · AI · contact PI
Innate NKT Cells in HIV Infection$339,664
R37 · FY2011 · AI · contact PI
A novel APOBEC-based vaccine approach for HIV$219,237
R21 · FY2011 · AI · contact PI
Protective immunity in HIV Highly exposed but uninfected subjects$191,194
R21 · FY2011 · AI · contact PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection$471,443
P01 · FY2010 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$399,729
R01 · FY2010 · AI · contact PI
T Regulatory Cells in HIV Infection$363,832
R01 · FY2010 · AI · contact PI
Innate NKT Cells in HIV Infection$288,007
R37 · FY2010 · AI · contact PI
Protective immunity in HIV Highly exposed but uninfected subjects$231,750
R21 · FY2010 · AI · contact PI
Protective immunity in HIV Highly exposed but uninfected subjects$224,025
R21 · FY2010 · AI · contact PI
An endogenous retroelement vaccine against HIV-1$424,875
R56 · FY2009 · AI · contact PI
Human Endogenous Retroelements in HIV Immunopathogenesis$387,484
R01 · FY2009 · AI · contact PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection$377,195
P01 · FY2009 · AI · contact PI
T Regulatory Cells in HIV Infection$367,507
R01 · FY2009 · AI · contact PI
Cell Mediated Immunity in HIV Infected Children$293,864
R01 · FY2009 · AI · contact PI
Innate NKT Cells in HIV Infection$290,916
R37 · FY2009 · AI · contact PI
NK Cells and HIV Infection$187,254
P01 · FY2009 · AI · contact PI
T Regulatory Cells in HIV Infection$367,415
R01 · FY2008 · AI · contact PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection$348,465
P01 · FY2008 · AI · contact PI
Cell Mediated Immunity in HIV Infected Children$293,583
R01 · FY2008 · AI · contact PI
Innate NKT Cells in HIV Infection$290,916
R37 · FY2008 · AI · contact PI
NK Cells and HIV Infection$228,270
P01 · FY2008 · AI · contact PI
NK Cells and HIV Infection$385,001
P01 · FY2007 · AI · contact PI
Cell Mediated Immunity in HIV Infected Children$312,134
R01 · FY2007 · AI · contact PI
Innate NKT Cells in HIV Infection$309,300
R37 · FY2007 · AI · contact PI
Protective HIV-Specific CD8+ T Cells in Early HIV Infection$307,008
P01 · FY2007 · AI · contact PI
Viral Tropism and Immune Control in HIV$186,918
R21 · FY2007 · AI · contact PI
NK Cells and HIV Infection$398,321
P01 · FY2006 · AI · contact PI
T Regulatory Cells in HIV Infection$386,896
R01 · FY2006 · AI · contact PI
Cell Mediated Immunity in HIV Infected Children$349,657
R01 · FY2006 · AI · contact PI
Innate NKT Cells in HIV Infection$185,148
R01 · FY2006 · AI · contact PI
Innate NKT Cells in HIV Infection$181,414
R01 · FY2006 · AI · contact PI
Viral Tropism and Immune Control in HIV$167,617
R21 · FY2006 · AI · contact PI
Viral Tropism and Immune Control in HIV$78,342
R21 · FY2006 · AI · contact PI
Innate NKT Cells in HIV Infection$450,000
R01 · FY2005 · AI
Cell Mediated Immunity in HIV Infected Children$317,318
R01 · FY2005 · AI
T Regulatory Cells in HIV Infection$220,377
R21 · FY2005 · AI
NK Cells and HIV Infection$196,338
P01 · FY2005 · AI
Innate NKT Cells in HIV Infection$450,000
R01 · FY2004 · AI
Cell Mediated Immunity in HIV Infected Children$374,267
R21 · FY2004 · AI
T Regulatory Cells in HIV Infection$240,952
R21 · FY2004 · AI
Innate NKT Cells in HIV Infection$398,000
R01 · FY2003 · AI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION$352,032
R01 · FY2003 · AI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION$306,289
R01 · FY2003 · AI
Innate NKT Cells in HIV Infection$418,000
R01 · FY2002 · AI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION$341,781
R01 · FY2002 · AI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION$260,036
R01 · FY2002 · AI
HIV Specific T-Cells in Mucosal Tissues$0
U19 · FY2002 · AI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION$331,828
R01 · FY2001 · AI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION$288,702
R01 · FY2001 · AI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION$239,303
R01 · FY2000 · AI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION$224,079
R01 · FY2000 · AI
HIV VARIATION AND CROSS CLADE CTL RECOGNITION$104,382
R01 · FY2000 · AI
DYNAMICS OF HIV1 SPECIFIC CTL IN HIV1 INFECTION$82,857
R01 · FY2000 · AI